SavedAdd your journal

Journals / Journal of critical and intensive care (Online) / 2020 / Cilt: 11 - Sayı: 1

Convalescent Plasma and Mesenchymal Stem Cell Therapy

Neriman Defne ALTINTAŞ
Pages
41–42
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, mesenchymal stem celltherapy for COVID-19 should only be considered in the context of a trial.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Since there are no currently accepted therapies for corona virus disease 2019 (COVID-2019), worldwidesearch for treatment options are ongoing.
📊
Key Findings & Data:Convalescent plasma therapy and mesenchymal stem cell therapyare considered as two of potential options.
💡
Conclusion & Impact:However, mesenchymal stem celltherapy for COVID-19 should only be considered in the context of a trial.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Since there are no currently accepted therapies for corona virus disease 2019 (COVID-2019), worldwidesearch for treatment options are ongoing. Convalescent plasma therapy and mesenchymal stem cell therapyare considered as two of potential options. Convalescent plasma therapy may be recommended early duringthe course of severe or rapidly progressive illness, despite paucity of evidence. However, mesenchymal stem celltherapy for COVID-19 should only be considered in the context of a trial.

🔖

Cite This Article

ALTINTAŞ, N. D. (2022). Convalescent Plasma and Mesenchymal Stem Cell Therapy. Journal of critical and intensive care (Online), Cilt: 11 - Sayı: 1, 41–42. https://ajindex.com/articles/562299

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;30(4):1545-1548 2. Valk SJ, Piechotta V, Chai KL, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: A Rapid Review. Cochrane Database Syst Rev. 2020 May 14;5:CD013600. doi: 10.1002/14651858.CD013600. 3. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. The feasibility ofconvalescent plasma therapy in severe COVID-19 patients: apilot study. medRxiv 2020. 4. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020.4783. 5. Wan Y, Shang J, Sun S, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol. 2020;94(5):e02015-19. 6. T.C. Sağlık Bakanlığı Sağlık Hizmetleri Genel Müdürlüğü Kan ve Kan Ürünleri Dairesi Başkanlığı COVID-19 immün (konvalesan) plazma tedarik ve klinik kullanım rehberi, Nisan 2020 https://covid19bilgi. saglik.gov.tr 7. Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216-228. 8. Metcalf SM. Mesenchymal stem cells and management of COVID-19 pneumonia. Medicine in Drug Discovery. 2020;5:100019. 9. Atluri S, Manchikanti L, Hirsch JA. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use. Pain Physician 2020; 23:E71-E83.